Oct 30, 2018
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Oct 29, 2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Oct 22, 2018
Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
Oct 09, 2018
New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
Sep 07, 2018
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Aug 02, 2018
Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
Jul 26, 2018
Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
Jun 28, 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
May 30, 2018
Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
May 21, 2018
New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score(TM) Test in Guiding Treatment Decisions
May 09, 2018
Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
May 02, 2018
Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
Apr 26, 2018
Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2018
Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
Mar 30, 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Mar 08, 2018
Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
Feb 26, 2018
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect(TM) Test to Predict Treatment Response in Metastatic Disease
Feb 22, 2018
Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
Feb 05, 2018
Oncotype DX® Genomic Prostate Score(TM) Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care
Dec 21, 2017
Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference